Norveġja -
Norveġiż -
Statens legemiddelverk
amlodipin sandoz 10 mg
sandoz a/s - amlodipinbesilat - tablett - 10 mg
Norveġja -
Norveġiż -
Statens legemiddelverk
norvasc 10 mg
upjohn eesv - amlodipinbesilat - tablett - 10 mg
Norveġja -
Norveġiż -
Statens legemiddelverk
norvasc 5 mg
upjohn eesv - amlodipinbesilat - tablett - 5 mg
Norveġja -
Norveġiż -
Statens legemiddelverk
sporanox 100 mg
janssen-cilag as - itrakonazol - kapsel, hard - 100 mg
Norveġja -
Norveġiż -
Statens legemiddelverk
sevikar 40 mg / 5 mg
daiichi sankyo europe gmbh - olmesartanmedoksomil / amlodipinbesilat - tablett, filmdrasjert - 40 mg / 5 mg
Norveġja -
Norveġiż -
Statens legemiddelverk
sevikar 20 mg / 5 mg
daiichi sankyo europe gmbh - olmesartanmedoksomil / amlodipinbesilat - tablett, filmdrasjert - 20 mg / 5 mg
Norveġja -
Norveġiż -
Statens legemiddelverk
sevikar 40 mg / 10 mg
daiichi sankyo europe gmbh - olmesartanmedoksomil / amlodipinbesilat - tablett, filmdrasjert - 40 mg / 10 mg
Norveġja -
Norveġiż -
Statens legemiddelverk
amlodipin accord 5 mg
accord healthcare b.v. - amlodipinbesilat - tablett - 5 mg
Norveġja -
Norveġiż -
Statens legemiddelverk
amlodipin accord 10 mg
accord healthcare b.v. - amlodipinbesilat - tablett - 10 mg
Unjoni Ewropea -
Norveġiż -
EMA (European Medicines Agency)
tukysa
seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - antineoplastiske midler - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.